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phosphatidylinositol 3-kinase signaling pathway in organ of 
Corti explants exposed to the NF-kappaB inhibitor reduced 
caspase-3 activation. These data link NF-kappaB-dependent 
hair cell death to phosphatidylinositol 3-kinase signaling. 
 Copyright © 2007 S. Karger AG, Basel 
 1. Introduction 
 Accurate statistics about hearing loss are not easy to 
obtain, however it is estimated that close to 250 million 
people worldwide suffer from some form of hearing im-
pairment (http://www.who.org). One in every 1000 chil-
dren are deaf by the age of 3 as a result of a number of 
inherited conditions, premature birth or complications 
during birth [Nadol, 1993]. In adults, hearing loss is often 
gradual and for many people begins around age 55, or it 
can be sudden, resulting from injury or infection. Other 
common causes of hearing impairment include exposure 
to intense sound (i.e. noise-induced hearing loss) and 
treatment with damaging medication (e.g. aminoglyco-
side antibiotics, anticancer drugs such as carboplatin and 
cisplatin, some loop diuretics and malaria medicine) 
[Huang et al., 2000; Johnsson et al., 1981; Yorgason et al., 
2006]. In most cases of hearing loss, the cause is linked to 
degeneration and death of cochlear sensory elements (i.e. 
hair cells). Since hair cells (HCs) in mammals do not re-
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 Abstract 
 Hair cells are the most vulnerable elements in the inner ear 
and their degeneration is the most common cause of hear-
ing loss. In the last few years progress has been made in un-
covering the molecular mechanisms involved in hair cell 
damage and death. However, little is known about factors 
important for hair cell survival. Recently, it has been demon-
strated that the transcription factor NF-kappaB is required 
for survival of immature auditory hair cells in vitro. Here we 
used DNA microarray technology to explore NF-kappaB 
downstream events in organ of Corti explants of postnatal 
day-5 Sprague-Dawley rats which were exposed to a cell-
permeable NF-kappaB-inhibitory peptide. Gene expression 
was analyzed using DNA microarray technology. Genes were 
selected on the basis of comparative analysis, which reliably 
distinguished the NF-kappaB inhibitor-treated samples from 
control samples. Interestingly, among the up-regulated 
genes was the gene coding for the regulatory subunit of 
phosphatidylinositol 3-kinase. Moreover, inhibition of the 
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generate, this type of hearing loss is irreversible. A de-
tailed understanding of the molecular events involved in 
HC damage and death is essential for developing prophy-
lactic and therapeutic strategies to prevent hearing loss 
associated with HC damage and death.  
 Over the past few years considerable progress has been 
made in discovering factors that mediate HC death, how-
ever, little is known about factors important for HC sur-
vival. Recently, we could demonstrate that NF-kappaB, a 
transcription factor that plays a major role in the regula-
tion of many apoptosis- and stress-related genes, is re-
quired for the survival of immature auditory HCs in vitro 
[Nagy et al., 2005]. In most cells, NF-kappaB is kept inac-
tive in the cytoplasm through interaction with I-kappaB. 
Nuclear translocation occurs after stimulus-induced 
degradation of I-kappaB. In addition to the inducible 
form, a constitutive active NF-kappaB has been described 
in different cell types such as photoreceptor cells in the 
eye and cortical neurons [Kaltschmidt et al., 1994; Krish-
namoorthy et al., 1999]. Similar to these reports we found 
a constitutively active form of NF-kappaB in the organ of 
Corti (OC) of 5-day-old rats. Selective inhibition of NF-
kappaB in vitro caused massive degeneration of HCs 
within 24 h of inhibitor application [Nagy et al., 2005]. 
These data suggest an important role for NF-kappaB in 
mediating survival of immature auditory HCs. We initi-
ated this study to explore NF-kappaB downstream events 
that contribute to HC survival in the immature mamma-
lian cochlea. 
 2. Materials and Methods 
 2.1. Animal Procedures 
 All animal procedures were carried out according to protocols 
approved by the Kantonales Veterinäramt, Zurich, Switzerland. 
Postnatal day 5 (p5) Sprague-Dawley rats (Harlan, The Nether-
lands) were utilized throughout the study.  
 2.2. Organ Culture 
 Animals were sacrificed and the cochleae carefully dissected 
to separate the OC from the spiral ganglion, stria vascularis and 
Reissner’s membrane. The organs were placed into 0.4-  m cul-
ture plate inserts (Millipore AG, Switzerland) and maintained in 
Dulbecco’s modified Eagle medium, supplemented with 10% fetal 
calf serum, 25 m M HEPES and 30 U/ml penicillin (Invitrogen AG, 
Switzerland). In all experiments, an 8-hour period was allowed 
for the explants to recover from the isolation procedure before 
further treatments [Sobkowicz et al., 1993]. For the time-course 
experiment, explants were exposed for 6, 12, and 24 h, respec-
tively, to the NF-kappaB inhibitor, while control explants were 
kept in culture medium alone or were exposed to the inactive con-
trol NF-kappaB inhibitor for 24 h (7 OC explants per sample). For 
the triplicate experiment, OC explants were exposed to the NF-
kappaB inhibitor for 6 h, control explants were kept in culture 
medium alone or were exposed for 6 h to the inactive control NF-
kappaB inhibitor (7 OC explants per sample). Each experiment 
was performed 3 times. 
 2.3. Inhibition of NF-kappaB Activity 
 To inhibit NF-kappaB activity, an HPLC-purified synthetic 
inhibitor (NF-kappaB inhibitor, AAVALLPAVLLALLAPVQR-
KRQKLMP, Santa Cruz Biotechnology Inc., Santa Cruz, Calif., 
USA) was added to the cell culture medium at the final concentra-
tion of 25   g/ml. We have previously shown that this compound 
and concentration causes HC loss [Nagy et al., 2005]. In the con-
trol experiments, an inactive control for the NF-kappaB inhibitor 
was used (NF-kappaB control, AAVALLPAVLLALLAPVQRDG-
QKLMP, Santa Cruz Biotechnology Inc.) at the same final con-
centration. 
 2.4. Inhibition of Phosphatidylinositol 3-Kinase Activity 
 Liquid LY 294002 (Calbiochem, Merck Biosciences GmbH, 
Germany), a highly specific, cell-permeable phosphatidylinositol 
3-kinase (PI3-K) inhibitor was added to the cell culture medium 
at the final concentration of 20   M . OC explants were first pre-
treated with LY 294002 for 2 h. Following pretreatment, a medium 
change was performed and samples were treated either with the 
NF-kappaB inhibitor (as described above) and LY 294002 simul-
taneously, or only LY 294002, for 24 h. 
 2.5. RNA Extraction from the OC 
 Total RNA was prepared from the cultured OC explants. Im-
mediately following treatment, tissue was placed in RNAlater 
(Qiagen AG, Switzerland) for a period of 2 days. Seven OC ex-
plants were pooled in one sample in order to obtain enough mate-
rial for further study. RNA was prepared using the RNAeasy Mini 
Kit (Qiagen AG, Switzerland) according to manufacturer’s in-
structions. DNase I treatment was performed directly on the col-
umns, also following the supplied protocol. The quality of the 
isolated RNA was determined with a NanoDrop ND 1000 (Nano-
Drop Technologies, Delaware, Ohio, USA) and Bioanalyzer 2100 
(Agilent, Waldbronn, Germany). Only those samples with a 
260/280-nm ratio between 1.8 and 2.1 and a 28S/18S ratio within 
1.5–2 were further processed. 
 2.6. Description of the Time-Course Microarray Experiments 
 2.6.1. cRNA Preparation. Total RNA (100 ng) was reverse-
transcribed into double-stranded cDNA with the Two-Cycle 
cDNA Synthesis Kit (Affymetrix Inc., P/N 900494, Santa Clara, 
Calif., USA). The double-stranded cDNA was purified using a 
Sample Cleanup Module (Affymetrix Inc., P/N 900371). The pu-
rified double-stranded cDNA was in vitro transcribed in the pres-
ence of biotin-labeled nucleotides using a IVT Labeling Kit (Af-
fymetrix Inc., P/N 900449). The biotinylated cRNA was purified 
using a Sample Cleanup Module (Affymetrix Inc., P/N 900371) 
and its quality and quantity were determined using NanoDrop 
ND 1000 and Bioanalyzer 2100.  
 2.6.2. Array Hybridization. Biotin-labeled cRNA samples (15 
  g) were fragmented randomly to 35–200 bp at 94  °  C in Fragmen-
tation Buffer (Affymetrix Inc., P/N 900371) and mixed in 300   l 
of hybridization buffer containing a hybridization control cRNA 
and control Oligo B2 (Affymetrix Inc., P/N 900454), 0.1 mg/ml 
herring sperm DNA and 0.5 mg/ml acetylated bovine serum al-
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bumin in 2-(4-morpholino)-ethane sulfonic acid buffer, pH 6.7, 
before hybridization to GeneChip  Rat Genome 230 2.0 arrays for 
16 h at 45  °  C. Arrays were then washed using an Affymetrix Flu-
idics Station 450 EukGE-WS2v5_450 protocol. An Affymetrix 
GeneChip Scanner 3000 (Affymetrix Inc.) was used to measure 
the fluorescent intensity emitted by the labeled target.  
 2.6.3. Statistical Analysis.  Raw data processing was performed 
using the Affymetrix GCOS 1.2 software (Affymetrix Inc.). After 
hybridization and scanning, probe cell intensities were calculated 
and summarized for the respective probe sets by means of the 
MAS5 algorithm [Hubbell et al., 2002]. To compare the expres-
sion values of the genes from chip to chip, global scaling was per-
formed, which resulted in the normalization of the trimmed 
mean of each chip to a target intensity (TGT value) of 500 as de-
tailed in the statistical algorithms description document of Af-
fymetrix (2002). Quality control measures were considered be-
fore performing the statistical analysis. These included adequate 
scaling factors (between 1 and 3 for all samples) and appropriate 
numbers of present calls calculated by application of a signed-
rank call algorithm [Liu et al., 2002]. The efficiency of the labeling 
reaction and the hybridization performance was controlled with 
the following parameters: present calls and optimal 3  /5  hybrid-
ization ratios (around 1) for the housekeeping genes (GAPDH and 
ACO7), for the poly-A spike in controls and the prokaryotic con-
trol (BIOB, BIOC, CREX, BIODN). 
 2.7. Description of the Triplicate Microarray Experiment 
 2.7.1. cRNA Preparation. Preparation of cRNA was performed 
as described in section 2.6.1 with the difference that total RNA 
samples (2   g) were reverse-transcribed into double-stranded 
cDNA with one-cycle cDNA synthesis kit (Affymetrix Inc., P/N 
900431).  
 2.7.2. Array Hybridization. Array hybridization was per-
formed as described in 2.6.2. 
 2.7.3. Statistical Analysis. Statistical analysis was performed as 
described in 2.6.3.  
 2.8. DNA Chip Analysis 
 Analysis of the microarray data was performed using DNA 
chip (dChip) software [Cheng and Wing, 2001], version June 27, 
2005 (available at: http://www.dchip.org, a detailed description of 
model-based analysis of oligonucleotide arrays can be found at 
this website). Individual array intensities were normalized to the 
array with median overall intensity using the Invariant Set of 
Normalization method (per default). Model-based expression 
values were computed using the PM/MM difference model, mea-
surement error was considered when averaging. In the main ex-
periment, the following comparison criteria were used to assess 
differentially expressed genes between the baseline set (B = three 
Nt groups and three Mut_6h-treated groups) and the experiment 
set (E = three Inh_6h-treated groups): (i) lower 90% confidence 
bound of fold change; (ii) E/B  1 1.2, B/E  1 1.2; (iii) E – B  1 100,
B – E  1 100; (iv) p value for testing E = B  ^  0.05, P call of B  6 
20%, P call of E  6 20%. Filtering was applied to cutoff variation 
across samples after pooling of replicate assays to 0.5  ! standard 
deviation/mean  ! 100, P call % in the arrays used  6 20%, and ex-
pression level  6 20 in  6 50% samples. Finally, clustering was per-
formed with setting the p value threshold for calling significant 
clusters between 0.001 and 0.05. The results are displayed in the 
form of a clustering tree.  
 2.9. GeneSpring Analysis 
 GeneSpring 7.1 software package (Agilent Technologies, Inc.) 
was used as an alternative microarray analysis tool to double-
check data generated by dChip analysis. Affymetrix-generated.cel 
files were loaded into GeneSpring software. Preprocessing (i.e. 
chip background intensity adjustment) was performed using GC-
Robust Multiarray Analysis (GC-RMA), per default. Data were 
normalized across all chips using the median of each gene. Only 
measurements flagged as present and with the raw signal value of 
100 were filtered further using the cross-gene error model based 
on replicates (software supplier’s instructions were followed as de-
scribed in the analysis guide for cross-gene error model available 
at http://www.chem.agilent.com), p value cutoff was set at 0.05.  
 2.10. Real-Time PCR 
 TaqMan  Gene Expression Assays with probes Rn00580055_
m1 [cysteine-rich protein 61 (Cyr61)], Rn00564547_m1 [regula-
tory subunit of PI3-K (PI3-Kr1)], Rn00594145_m1 [cadherin-13 
(Cdh13)] and the endogenous controls Rn_00566655_m1 [beta-
glucuronidase (Gusb)] and beta actin (4352931E) were used to 
verify changes in gene expression levels. Assays were performed 
in the ABI PRISM 7700 Sequence Detection System according to 
manufacturer’s protocol (Applied Biosystems, Applera Europe 
B.V., The Netherlands). For each reaction, cDNA samples were 
diluted 1:  10 and 1   l was used together with the TaqMan  Uni-
versal PCR Master Mix., No AmpErase  UNG (Applied Biosys-
tems, P/N 4234018, Applera Europe B.V., The Netherlands). After 
completion of 45 cycles at default settings, resulting amplification 
curves were examined and baseline values were set between cycles 
3 and 15 (no adjustment was necessary), log increase was observed 
to start at cycle 22. Expression of each target mRNA was calcu-
lated using the comparative C t  method, based on the threshold 
cycle (C t ) as 2 –cΔΔCt , where   C t  = C t, target  – C t, Gusb or beta-actin 
and   C t  =   C t, experiment condition  –   C t, control condition . Standard 
deviations (s) were calculated according to the formula s =
(s control condition 2  + s experiment condition 2 ) 1/2 .  
 2.11. Immunofluorescence 
 For immunofluorescence studies, OC explants were fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.2) and 
permeabilized with 5% Triton X-100 in PBS with 10% fetal bovine 
serum. To reduce unspecific binding sections were treated with 
PBS containing 2% bovine serum albumin for 30 min at room tem-
perature. The samples were then incubated with rabbit anti-PI3-K 
p85  polyclonal antibody (Z-8) (1:  50) overnight at 4  °  C. After re-
petitive washing in PBS, the samples were incubated with second-
ary anti-rabbit FITC-conjugated antibody (1:  100) for 2 h at room 
temperature. In the negative control, the primary antibody was re-
placed by PBS. Samples were visualized on a fluorescence micro-
scope (Olympus IX71) and photographed using AxioCam (Zeiss) 
immediately following staining. All antibodies were purchased 
from Santa Cruz Biotechnology Inc. (Santa Cruz, Calif., USA). 
 For phalloidin staining samples were incubated with a 1:  100 
dilution of F-actin binding Texas red-conjugated phalloidin 
T7471 (Invitrogen AG) for 1 h at room temperature. Visualization 
was performed on a Leica inverted confocal laser scanning
microscope with a red filter (excitation/emission wavelength 
596/615nm). Images were assembled by stacking 20 single digital 
scans (4   m in thickness) using Imaris  Image Processing Soft-
ware (Bitplane AG, Switzerland).  
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 2.12. Caspase-3 Activity Assay  
 Cultured OC explants were harvested in 10 m M HEPES, pH 
7.5, 2 m M EDTA and 0.1% CHAPS, supplemented with 5 m M 
DTT, 1 m M PMSF, 10   g/ml pepstatin A, 10   g/ml aprotinin and 
10   g/ml leupeptin. For each condition, 5 explants were pooled in 
order to obtain enough material for biochemical assays. Tissue 
was homogenized with Ultra-Turrax T8 (IKA-Werke GmbH, 
Germany) tissue homogenizer. Samples were then centrifuged at 
13,000 rpm for 20 min at 4  °  C, and supernatant mixed 1:  1 with 
caspase assay buffer (200 m M HEPES, pH 7.5, 1 m M EDTA, 20% 
sucrose, 0.2% CHAPS, 0.2 mg/ml bovine serum albumin, 20 m M 
DTT). Adenosine triphosphate (Invitrogen AG) and Ac-DEVD-
pNA (ALEXIS Corp., Switzerland) were added to the reaction 
mixtures at the final concentrations of 1 and 50 m M , respectively. 
Reactions were incubated for 3 h at 37  °  C. Following, the caspase-
3 activity was measured in a spectrophotometer (Tecan Trading 
AG, Switzerland) at wavelength 405 nm.  
 2.13. Statistical Analysis for Caspase Assays 
 Results obtained in the caspase activity assays were analyzed 
by an unpaired t test using GraphPad Prism 3.03 software (Graph-
Pad Software Inc.). The unpaired t test compares the means of two 
groups, assuming the data are sampled from Gaussian popula-
tions. Statistical significance is given in the form of p value and 
confidence interval. A p value of  ! 0.05 signifies that the differ-
ences observed in comparison of 2 samples are statistically sig-
nificant, i.e. that it is unlikely that the differences observed are 
due to a coincidence of random sampling. Data obtained in three 
independent experiments were used for analysis.  
 3. Results 
 3.1. Inhibition of NF-kappaB Activity in OC Explants 
Results in Gene Expression Changes Compared to 
Control Explants  
 To assess the time point at which global changes in gene 
expression occur in rat p5-old OC explants exposed to 25 
  g/ml NF-kappaB inhibitor, gene expression profiling was 
performed using GeneChip  Rat Genome 230 2.0 arrays 
from Affymetrix. In this experiment, out of 31099 se-
quence tags present on the gene chip, statistical analysis 
(p value between 0.001 and 0.05) identified 74 differen-
tially expressed genes 6 h after addition of the NF-kappaB 
inhibitor compared to untreated samples or samples treat-
ed with the inactive NF-kappaB inhibitor control ( fig. 1 , 
down-regulated genes are depicted in blue, up-regulated 
genes are depicted in red). A list containing a more detailed 
description of differentially expressed genes, as identified 
by dChip software, is provided in  table 1 . It must be noted 
that these data represent a single array sample employing 
specific experimental conditions, and the genes presented 
in  figure 1 are not to be regarded as reliably differentially 
expressed between the tested conditions. We used them as 
orientation for determining an early time-point at which 
NF-kappaB inhibition-induced gene expression changes 
could be observed in OC cultures.  
 3.2. After 6 h of NF-kappaB Inhibition, the OC 
Explants Do Not Show HC Loss 
 Previously, we have shown that caspase-3 activation in 
OC explants occurs as early as 6 h after treatment with the 
NF-kappaB inhibitor, with apoptotic HC death visible af-
ter 24 h [Nagy et al., 2005]. Here we extend the histological 
analysis to earlier points in time of 6 and 12 h, with an in-
hibitor concentration of 25   g/ml throughout the experi-
ments. Six hours of treatment did not result in any signifi-
cant HC loss, although the HC rows appeared slightly per-
turbed ( fig. 2 ). Twelve hours following treatment, visible 
damage to HC could be detected ( fig. 2 ). A total of 8 ex-
plants (from 4 animals) were examined for each condition; 
representative images are shown in  figure 2 .  
 3.3. The Regulatory Subunit of PI3-K Is Up-Regulated 
in HCs after NF-kappaB Inhibition  
 After determining that gene expression changes occur 
as early as 6 h following NF-kappaB inhibition, this time 
was chosen for further analysis in which the microarray 
experiments were performed in triplicates, and the data 
analyzed by dChip and GeneSpring software packages. 
Both comparative analyses gave overlapping results and 
have identified 14 genes, which reliably distinguished the 
NF-kappaB inhibitor-treated samples from control sam-
ples either cultured in medium alone or treated with the 
inactive control NF-kappaB inhibitor ( fig. 3 ). From 14 
genes, 2 were down-regulated, and 12 were up-regulated 
following NF-kappaB inhibition ( table 2 ).  
 Out of the 14 genes found in the replicate assays to be 
reliably differentially expressed in the NF-kappaB inhibi-
tor-treated group vs. the inactive control inhibitor group 
and the medium alone control group, two genes were se-
lected and their expression changes were then assessed 
using RT real-time PCR. The gene coding for PI3-Kr1 and 
the gene coding for Cyr61 were chosen for analysis be-
cause of previous reports linking NF-kappaB to these 
genes [D’Addario et al., 1999; Lin et al., 2004]. RT real-
time PCR confirmed up-regulation of PI3-Kr1 and Cyr61 
genes and down-regulation of the Cdh13 gene in NF-kap-
paB inhibitor-treated OC explants, as compared to un-
treated controls ( fig. 4 a–c). Moreover we could detect PI3-
Kr1 in inner and outer HC of the OC. PI3-Kr1 immuno-
reactivity was only present in HCs and not in any type of 
supporting cells. After inhibition of NF-kappaB the im-
munoreactivity was significantly increased ( fig. 5 ). 
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 Fig. 2. NF-kappaB inhibitor damages HCs. Middle turns of rat p5 
OC organs immunostained with phalloidin-rhodamine analyzed 
by immunofluorescence microscopy. Explants were treated with 
a specific NF-kappaB inhibitor for 0 (control, cultured in medium 
alone), 6, 12, and 24 h. There is progressive HC loss with increas-
ing time of exposure to the inhibitor. 
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1376193_at, Transcribed locus
1388596_at, coactosin-like 1 (Dictyostelium...
1392578_at, Matrix Gla protein
1367973_at, chemokine (C-C motif ) ligand 2
1392064_at, gb:BF400590 /DB_XREF=gi:1...
1372065_at, ADP-ribosyltransferase 3 (pre...
1385868_at, gb:AA875124 /DB_XREF=gi:4...
1395761_at, Similar to semaphorin A
1367930_at, growth associated protein 43
1382325_at, glycine C-acetyltransferase (2...
1369268_at, activating transcription factor 3
1385450_at, gb:AI454706 /DB_XREF=gi:4...
1377336_at, sema domain, immunoglobulin...
1389873_at, gb:BI282953 /DB_XREF=gi:1...
1395999_at, Transcribed locus
1370432_at, POU domain, class 3, transcri...
1393469_at, Similar to RIKEN cDNA 1110...
1383218_at, LOC361928
1393722_at, gb:BE 108945 /DB_XREF=gi:8...
1387112_at, proteolipid protein
1377114_at, gb:AI410861 /DB_XREF=gi:4...
1398387_at, Unknown (protein for MGC:72...
1379382_at, Transcribed locus
1378252_at, Transcribed locus
1386662_at, Transcribed locus
1368148_at, nerve growth factor receptor (...
1370963_at, growth arrest speciﬁc 7
1395095_at, leucine zipper-EF-hand contai...
1379834_at, Transcribed locus
1386785_a_at, LRRGT00193
1377971_at, LRRGT00193
1387376_at, aldehyde oxidase 1
1385874_at, Transcribed locus
1389840_at, splicing factor 3b, subunit 1
1380696_at, Similar to RIKEN cDNA C230...
1378152_at, gb:Al170349 /DB_XREF=gi:3...
1396036_at, Ral GEF with PH domain and...
1375535_at, gb:Al103917 /DB_XREF=gi:3...
1382068_at, gb:AA963991 /DB_XREF=gi:4...
1390987_at, Transcribed locus
1379571_at, plakophilin 4 (predicted)
1390549_at, adiponectin receptor 2 (predict...
1395327_at, CD36 antigen (collagen type I...
1371361_at, gb:BI278826 /DB_XREF=gi:1...
1385408_at, gb:BI288589 /DB_XREF=gi:1...
1368238_at, pancreatitis-associated protein
1385354_at, integrin alpha 8
1395629_at, Transcribed locus
1382862_at, gb:BE119506 /DB_XREF=gi:8...
1388500_at, Transcribed locus
1379603_at, Transcribed locus
1375016_at, Transcribed locus
1370912_at, Heat shock 70kD protein 1A
1376917_at, gb:BF388585/DB_XREF=gi:1...
1370372_at, RASD family, member 2
1371603_at, proline-rich polypeptide 3
1384695_at, uroplakin 3A (predicted)
1392077_at, Chromosome 11 open reading...
1377706_x_at, gb:BF549971 /DB_XREF=g...
1377705_at, gb:BF549971 /DB_XREF=gi:1...
1387338_s_at, BCL2-like 11 (apoptosis faci...
1396803_at, similar to Tho2
1390398_at, Bone morphogenetic protein r...
1382118_at, gb:BE104676/DB_XREF=gi:8...
1388138_at, thrombospondin 4
1370845_at, ectonucleoside triphosphate di...
1387938_at, brain and acute leukemia, cyto...
1391771_at, ATPase, Ca++ transporting, c...
1378340_at, similar to hypothetical protein...
1377173_at, Transcribed locus, moderately...
1368299_at, G protein-coupled receptor 83
1393348_at, Transcribed locus
1385205_at, gb:BF409092 /DB_XREF=gi:1...
1392791_at, Transcribed locus
Gene
 Fig. 1. dChip clustering tree representing the time-course experi-
ment data. Differentially expressed genes in the OC explants fol-
lowing 6-, 12-, and 24-hour treatment with a specific NF-kappaB 
inhibitor (Inh), compared to untreated (Nt) and inactive inhibitor 
control (Mut)-exposed OC explants. Each row represents a gene, 
and each column represents a sample. The dendrogram on the left 
illustrates the results of clustering, where genes close to each oth-
er have high similarity in their standardized values across all sam-
ples. The expression level of each gene is standardized to have 
mean 0 and standard deviation 1. Red color represents expression 
levels above mean expression and blue color represents expression 
lower than mean.  
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Gene symbol Description NCBI GeneID 
or locus
Fold 
change
1 EST AA819658 +1.49
2 Cotl1_predicted coactosin-like 1 (predicted) 361422 +1.44
3 Mgp matrix Gla protein 5333 +1.9
4 Ccl2 chemokine (C-C motif) ligand 2 24770 +1.84
5 EST BF400590 +1.74
6 EST AA964492 +1.58
7 Art3_predicted ADP-ribosyltransferase 3 (predicted) 305235 +1.43
8 EST AA875124 +1.36
9 EST BF409092 +2.54
10 EST AI007775 +1.64
11 Sema3b_predicted secreted, (semaphorin) 3B (predicted) 63142 +1.39
12 Gap43 growth-associated protein 43 29423 +1.82
13 Gcat_predicted lycine C-acetyltransferase (predicted) 366959 +1.49
14 Atf3 activating transcription factor 3 25389 +1.65
15 EST AI454706 +1.49
16 Sema3b_predicted secreted, (semaphorin) 3B (predicted) 363142 +1.39
17 EST BI282953 +1.49
18 EST BF419607 +1.48
19 Pou3f1 POU domain, class 3, transcription factor 1 192110 +1.91
20 RGD1307901_ predicted similar to RIKEN cDNA 1110001E1 (predicted) 306327 +1.43
21 LOC361928 361928 +1.37
22 EST BE108945 +1.34 
23 Plp proteolipid protein 24943 +1.51
24 EST AI410861 +1.4
25 RGD:735075 unknown (protein for MGC: 72614) 310540 +1.53
26 EST AI144865 +1.6
27 Gpr83 G protein-coupled receptor 83 140595 +1.63
28 EST BE104535 +1.39
29 Thbs4 thrombospondin 4 29220 +1.48
30 Entpd2 ectonucleoside triphosphate diphosphohydrolase 2 64467 +1.62
32 Baalc brain and acute leukemia, cytoplasmic 1 140720 +1.63
33 Atp2a2 ATPase, Ca++ transporting slow twitch 2 29693 +1.72
34 LOC289480 similar to hypothetical protein MGC35043 89480 +2.06
35 Ngfr nerve growth factor receptor (TNFR superfamily, member 16) 24596 +1.86
36 Gas7 growth arrest-specific 7 85246 +1.52
37 Letm2_predicted leucine zipper-EF-hand containing transmembrane protein 2
(predicted)
361169 –2.21
38 EST AI029745 –1.63
39 EST BF553981 –5.14
40 Aox1 aldehyde oxidase 1 54349 –2.47
41 EST BG378771 –1.84
42 EST BF559982 –1.94
43 EST BG374488 –2.82
44 EST AI103917 –2.2
45 Ralgps2_predicted Ral GEF with PH domain and SH3 binding motif 2 (predicted) 304887 –1.51
46 EST AI170349 –1.63 
47 RGD1310037_ predicted similar to RIKEN cDNA C230093N12 (predicted) 365903 –2.74
48 Sf3b1 splicing factor 3b, subunit 1 84486 –1.33
49 EST AA956418 –2.19
50 EST AA963991 –1.48
51 Pap pancreatitis-associated protein 24618 –1.43
52 EST BI288589 –1.64
53 EST BI278826 –1.42
 Table 1. Time-course microarray experiment data 
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 3.4. Inhibition of PI3-K Reduces Caspase-3 Activation 
in OC Explants Exposed to an NF-kappaB Inhibitor 
 Activation of caspases (cysteine-aspartatic acid prote-
ases) is an early event in programmed cell death. Caspas-
es initiate cellular breakdown by degrading specific pro-
teins. Activation of caspase-3 plays a key role in the apo-
ptotic process, and once it has been activated, the program 
for cell death is irreversibly activated. In a recent report 
we showed that caspase-3 activity increases in the OC fol-
lowing inhibition of NF-kappaB activity [Nagy et al., 
2005], suggesting that HC death following NF-kappaB in-
hibition occurs by an apoptosis-directed pathway. Cas-
pase activity assays utilizing Ac-DEVD-pNA caspase-3 
substrate (Alexis Biochemicals) indicated that inhibition 
of PI3-K significantly (p = 0.0378) reduced caspase-3 ac-
tivity in OC explants exposed to the NF-kappaB inhibitor 
( fig. 6 ). As a negative control the baseline buffer and as a 
positive control an active human recombinant caspase-3 
(Alexis Biochemicals) were used (data not shown). 
 4. Discussion 
 Inhibition of NF-kappaB activity in OC explants of p5 
Sprague-Dawley rats resulted in up-regulation of 12 
genes, among them the gene coding for PI3-Kr1, and 
down-regulation of 2 genes. Moreover, using cell culture 
experiments we show that the inhibition of the PI3-K sig-
naling pathway, using a specific inhibitor, reduced cas-
pase-3 activation in OC explants exposed to a specific 
NF-kappaB inhibitor. Moreover, we found with immuo-
fluorescence PI3-Kr1 exclusively in HCs and not in sup-
porting cells. These data provide evidence for involve-
ment of the PI3-K signaling pathway in NF-kappaB-de-
pendent HC death.  
 The NF-kappaB family of transcription factors are key 
regulators of many biological processes such as immu-
nity, cell survival and apoptosis [Karin and Greten, 2005]. 
However, their function in the inner ear is only partially 
understood. NF-kappaB expression has been found in 
Gene symbol Description NCBI GeneID 
or locus
Fold 
change
54 Scarb2 CD36 antigen
(collagen type I receptor, thrombospondin receptor)-like 2
117106 –1.75
55 Adipor2_predicted adiponectin receptor 2 (predicted) 12670 –1.51
56 Pkp4_predicted plakophilin 4 (predicted) 295625 –1.94
57 EST AI406858 –1.81
58 Itga8 integrin alpha 8 84381 –1.57
59 EST BE119506 –1.35
60 EST BE105336 –1.49
61 LOC313308 similar to THO complex 2 313308 –1.6
62 Bcl2l11 BCL2-like 11 (apoptosis facilitator) 64547 –17.6
63 EST BF549971 –1.56
64 C11orf8 chromosome 11 open reading frame 8 362185 –1.51
65 EST AI180252 –1.27
66 Upk3a_predicted uroplakin 3A (predicted) 315190 –1.52
67 RGD:1303270 proline-rich polypeptide 3 361788 –1.58
68 EST BE116890 –1.64
69 Rasd2 RASD family, member 2 171099 –1.34
70 Bmpr1a bone morphogenetic protein receptor, type 1A 81507 –1.37
71 EST BF388585 –1.46 
72 Hspa1a heat shock 70-kDa protein 1A 24472 –1.6
73 EST AI406912 –1.64 
74 EST BE104676 –1.38
More detailed list of genes whose expression was altered by NF-kappaB inhibition already after 6 h compared to untreated samples 
or samples treated with the inactive NF-kappaB inhibitor control and their corresponding ‘fold change’ values obtained by dChip 
analysis. Numbers 1–36 represent up-regulation of gene expression; numbers 37–74 represent down-regulation of gene expression.
EST = Expressed sequence Taq.
 
 
 Table 1  (continued) 
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 Fig. 4. Quantification of RT real-time PCR signals of PI3-Kr1 ( a ), 
Cdh13 ( c )  and Cyr61 ( b )  in untreated (control) and NF-kappaB-
treated samples. Relative quantification of RT real-time PCR sig-
nals using the comparative C t  method is shown. Gusb serves as 
active endogenous control to which target mRNA was normal-
ized; average values were calculated based on results from three 
independent experiments. Standard deviation is given by error 
bars. Expression values from dChip and GeneSpring are included 
for comparison. 
Cadherin 13
Nt Mut Inh
1 2 3 4 5 6 7 8 9
Baseline
(B)
Experiment
(E)
Transcribed locus
Transcribed locus
Transcribed locus
Phosphatidylinositol 3-kinase
DNA methyltransferase 3A
Similar to transcription repressor p66
Similar to mKIAA 1757 protein
EH-domain containing 3
Cysteine-rich protein 61
gb:AA963991
Semaphorin 6A1
GERp95
RAB14
 Fig. 3. Triplicate microarray data. Differentially expressed genes. 
Replicate assays from the same experimental condition (lanes 1, 
2, and 3 represent untreated controls, lanes 4, 5, and 6 represent 
6-hour treatment with the inactive NF-kappaB inhibitor control, 
whereas lanes 7, 8, and 9 represent 6-hour treatment with the NF-
kappaB inhibitor) were pooled using a weighted averaging meth-
od and comparative analysis was performed using dChip soft-
ware. After filtering, 14 genes depicted were identified as being 
reliably differentially expressed between the different groups 
(format is the same as in fig. 1). 
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the murine cisplatin-treated cochlea, mostly in the stria 
vascularis and the spiral ligament [Watanabe et al., 2002]. 
Recently, it has been reported that NF-kappaB has a pro-
tective role in kanamycin-induced HC death in adult 
mice [Jiang et al., 2005]. In addition, we have shown that 
NF-kappaB is found in the immature OC in a constitutive 
active form and that inhibition of its activity results in 
massive HC degeneration [Nagy et al., 2005]. In order to 
investigate downstream events that contribute to apop-
totic HC death in response to NF-kappaB inhibition in 
the immature cochlea, we initiated this study. 
 We primarily wanted to gain insight into early gene 
expression changes that occur in the OC after NF-kap-
paB inhibition, which ultimately lead to, but occur prior 
NCBI locus Gene name Fold change 
dChip
Fold change 
GeneSpring
BI282750 cadherin-13 –1.4780.12 –1.4580.21
BF400182 transcribed locus –1.8280.08 –1.6480.13
AA923974 RAB14 +1.3980.14 +1.4380.18
AI102401 transcribed locus +1.5280.31 +1.4680.37
BM391695 transcribed locus +1.4980.09 +1.4180.15
D64048 phosphatidylinositol 3-kinase +3.9780.42 +4.2180.51
AI029751 DNA methyltransferase 3A +1.6080.34 +1.5380.39
BE109744 similar to transcription repressor p66 +2.1980.32 +1.9280.42
BF281131 GERp95 +1.7780.43 +1.4680.52
AW526768 similar to mKIAA 1757 protein +2.1780.49 +1.1380.50
AA957585 EH-domain containing 3 +1.3780.17 +1.6780.23
NM_031327 cysteine-rich protein 61 +1.4680.27 +2.9980.46
AA963991 Gb:AA963991 +1.4680.15 +1.3980.19
BM387083 semaphorin 6A 1 +1.6180.25 +1.4680.28
Genes of interest whose expression reliably differs in NF-kappaB inhibitor-treated 
versus control arrays. Fold changes in expression levels with respect to the untreated 
control samples (8 standard deviation between triplicate experiments) are given.
 
 
 Table 2. Triplicate microarray data  
 Fig. 5. Immunofluorescence showing PI3-
Kr1 in inner and outer HCs before ( a ) and 
after ( b ) treatment for 6 h with a NF-kap-
paB inhibitor; the right side shows immu-
nostaining for PI3-Kr1, the left side shows 
the corresponding phalloidin staining. 
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to the actual death of HCs. Two genes, encoding for Cyr61 
and PI3-Kr1, seemed to be most interesting because of the 
reports from the literature linking them to NF-kappaB 
[Beraud et al., 1999; Birkenkamp et al., 2004; Lin et al., 
2004]. Even though there are no data in the literature 
concerning the role of Cyr61 in the ear, Lin et al. [2004] 
report that MCF-7 cell lines overexpressing Cyr61 had 
significantly increased NF-kappaB activity compared 
with control cells. Furthermore, the NF-kappaB pathway 
was evidently activated in Cyr61-overexpressing gastric 
cancer cells [Lin et al., 2005]. Reports by Reddy et al. 
[1997], Beraud et al. [1999] and Birkenkamp et al. [2004] 
made a connection also between PI3-K and NF-kappaB. 
Real-time PCR confirmed down-regulation of Cdh13 in 
OC explants after NF-kappaB inhibition. The signifi-
cance of the changes in Cdh13 and Cyr61 expression in 
OC explants after NF-kappB inhibition has to be eluci-
dated in future studies. In this study we focus on the PI3-
K signaling pathway. 
 PI3-K generates phosphorylated phosphoinositides 
that serve as crucial second messengers for a wide range 
of biological functions such a cell survival and differen-
tiation. The role of the PI3-K signaling pathway in the 
inner ear is poorly understood. It has been demonstrated 
that this pathway plays a role for S-phase entry of the ves-
tibular epithelia of both avian and mammalian species 
[Witte et al., 2001].  
 Recent studies in other cell types indicate a complex 
regulation of PI3-K activity involving a delicate balance 
between the regulatory subunits and functional PI3-K 
heterodimers consisting of regulatory and catalytic sub-
units [Fruman et al., 1998; Hallmann et al., 2003; Katso 
et al., 2001; Virkamaki et al., 1999]. In this study we found 
PI3-Kr1 up-regulated after NF-kappaB inhibition in OC 
explants. Moreover we found weak immunoreactivity of 
PI3-Kr1 in control explants, and strong immunoreactiv-
ity in OC explants exposed to the NF-kappaB inhibitor. 
In both cases PI3-Kr1 was detected in hair cells and not 
in supporting cells of the OC. This is very much in agree-
ment with findings by Beraud et al. [1999]. They have 
reported that PI3-Kr1 specifically associates with tyro-
sine-phosphorylated IkappaB-alpha after stimulation of 
T cells with pervanadate. This suggests that by sequester-
ing IkappaB-alpha, PI3-Kr1 is involved in an alternative 
pathway of activating NF-kappaB. Therefore it is possible 
that by increasing the expression of PI3-Kr1 HCs are try-
ing to reduce the impact of apoptosis caused by NF-kap-
paB inhibition. These findings suggest that up-regulation 
of the regulatory subunit of PI3-K upon NF-kappaB in-
hibition might work as a counterbalance to the process of 
apoptosis and help rescue the cells. 
 What about the role of PI3-K itself? Beraud et al. 
[1999], Birkenkamp et al. [2004] and Reddy et al. [1997] 
have found, under conditions when NF-kappaB was ac-
tivated, that inhibition of PI3-K resulted in reduction of 
NF-kappaB activity. In this study, however, inhibition of 
PI3-K activity with LY294002, a compound that affects 
the ATP binding site of the enzyme [Vlahos et al., 1994], 
reduced caspase-3 activity in OC explants exposed to a 
NF-kappaB inhibitor. It should be noted that inhibition 
of PI3-K under normal culturing conditions did not re-
sult in morphological changes of HCs. This suggests that, 
under conditions when NF-kappaB is inhibited, inhibi-
tion of PI3-K helps alleviate the effect of apoptosis. Why 
does inhibition of PI3-K not increase the effect of apo-
ptosis, as would be expected from the reports above? We 
suggest the following explanation: under conditions of 
NF-kappaB inhibition, the expression of the regulatory 
subunit of PI3-K in HCs is increased and it becomes in 
excess over the PI3-K heterodimers. It has been proposed 
that excess monomeric regulatory subunit competes with 
0
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 Fig. 6. Inhibition of phosphatidylinositol 3-kinase reduces cas-
pase-3 activity in OC exposed to an NF-kappaB inhibitor. Cas-
pase-3 activation assay; phosphatidylinositol 3-kinase inhibitor 
and control for NF-kappaB inhibitor (LY + Inh-Mut), phosphati-
dylinositol 3-kinase inhibitor and NF-kappaB inhibitor (LY + 
Inh), or NF-kappaB inhibitor (Inh). Baseline buffer and Ac-
DEVD-pNA activity (as measured in sample not containing pro-
tein lysates) were subtracted from each sample. Data bars repre-
sent mean values obtained in three independent experiments, and 
error bars represent standard deviation. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 5
:1
0:
32
 P
M
 NF-kappaB and Auditory Hair Cells  Audiol Neurotol 2007;12:209–220 219
functional PI3-K heterodimers [Hallmann et al., 2003]. 
Inhibition of the catalytic site of the enzyme by a specific 
inhibitor might contribute to shifting the balance to the 
side of the regulatory subunit, which, by sequestering the 
IkappaB-alpha, could help diminish the effect of inhibi-
tion of NF-kappaB and subsequently reduce apoptosis. 
However, additional experiments are required to confirm 
this hypothesis. 
 This study links the PI3-K pathway to NF-kappaB-de-
pendent HC death in the immature mammalian cochlea. 
However, one should be aware of several limitations of 
the methods used. First of all, since mature HCs cannot 
be maintained in vitro, we have used immature HCs for 
this study. Even though immature cochlea is an estab-
lished model for cellular and molecular studies concern-
ing various aspects of inner ear biology such as ototoxic-
ity [Pirvola et al., 2000], immature HCs can react differ-
entially than adult HCs to inhibition of intracellular 
signaling pathways. Therefore our data are limited to the 
immature mammalian cochlea. What might be the role 
of NF-kappaB in the mature cochlea? Recent studies in-
dicate a role for NF-kappaB in the mature cochlea: a study 
conducted with adult mice demonstrated that the redox 
state of the cochlea stimulates NF-kappaB activation [Ji-
ang et al., 2005]. In another study, adult mice lacking the 
NF-kappaB subunit p50 suffered from increased noise-
induced hearing loss compared to their wild-type litter-
mates [Lang et al., 2006]. It seems therefore that NF-kap-
paB plays an important role in the adult mammalian
cochlea. However, although the microarray data were an-
alyzed by two independent comparative analyses that 
gave overlapping results and the data were confirmed by 
RT real-time PCR and by using highly specific signal 
transduction pathway inhibitors, one must be aware that 
the use of microarray technology is not well established 
for the analysis of gene expression in the inner ear. Due 
to the fact that no inner ear array (no high-quality inner 
ear arrays commercially available at this time) has been 
used in this study, it is possible that some genes specifi-
cally differentially expressed in the OC were missed. Ad-
ditionally, we might have missed some genes because we 
applied very stringent filtering criteria for selecting the 
14 differentially expressed genes in the replicate experi-
ment. While such criteria contributed to the reliability of 
the data, they may have caused the loss of some genes. 
Another difficulty that arises when microarray technol-
ogy is applied to analysis of gene expression in the inner 
ear, is how to discern differences in cell type-specific ex-
pression, as there are different cell types in the OC of the 
inner ear. Therefore our microarray data reflect the glob-
al gene expression pattern from all the cells of the OC and 
not only of HCs. However, in a previous study [Nagy et 
al., 2005], we have shown that NF-kappaB is localized in 
the nuclei of HCs in the OC, suggesting that the molecu-
lar mechanisms involved after NF-kappaB inhibition are 
also localized in HCs.  
 Taken together, this study suggests that the PI3-K 
pathway is involved in the NF-kappaB-dependent HC 
death in the immature mammalian cochlea. The involve-
ment of other genes identified by the microarray experi-
ment described herein was not confirmed. Their role is 
currently unknown and will be addressed in further 
studies. 
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